{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:15:53Z","timestamp":1792185353674,"version":"4.4.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001245","name":"Jeffrey Modell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jaip.2022.08.025","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T13:13:20Z","timestamp":1661778800000},"page":"3088-3096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunosuppression in Patients With Primary Immunodeficiency\u2014Walking the Line"],"prefix":"10.1016","volume":"10","author":[{"given":"S. Shahzad","family":"Mustafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Jolles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.08.025_bib1","first-page":"1","article-title":"Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee","author":"Tangye","year":"2022","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib2","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"119","author":"Resnick","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.08.025_bib3","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jaip.2017.01.021","article-title":"British Lung Foundation\/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders","volume":"5","author":"Hurst","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.08.025_bib4","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1445-5994.1997.tb00934.x","article-title":"Lymphocytopenia in a hospital population\u2014what does it signify?","volume":"27","author":"Castelino","year":"1997","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.jaip.2022.08.025_bib5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.08.025_bib6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.anai.2019.07.014","article-title":"Autoimmunity in common variable immunodeficiency","volume":"123","author":"Agarwal","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s10875-016-0264-7","article-title":"Secondary antibody deficiency in glucocorticoid therapy clearly differs from primary antibody deficiency","volume":"36","author":"Wirsum","year":"2016","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2011.08880.x","article-title":"Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients","volume":"155","author":"Gobert","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2022.08.025_bib9","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jaip.2022.08.025_bib10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaip.2022.08.025_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s10875-012-9755-3","article-title":"Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID)","volume":"33","author":"Chase","year":"2013","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10875-017-0374-x","article-title":"Gastrointestinal manifestations in X-linked agammaglobulinemia","volume":"37","author":"Barmettler","year":"2017","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib14","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/acr.20037","article-title":"Neutropenia in patients receiving anti-tumor necrosis factor therapy","volume":"62","author":"Hastings","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaip.2022.08.025_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1081-1206(10)61228-8","article-title":"Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature","volume":"95","author":"Thatayatikom","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/ecco-jcc\/jjaa186","article-title":"TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review","volume":"15","author":"Muller","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jaip.2022.08.025_bib17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaip.2020.11.055","article-title":"Lifelong immune modulation versus hematopoietic cell therapy for inborn errors of immunity","volume":"9","author":"Cooper","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.08.025_bib18","first-page":"1","article-title":"Primary immune regulatory disorders and targeted therapies","volume":"38","author":"Koluk\u0131sa","year":"2021","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.jaip.2022.08.025_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1681\/ASN.V12162","article-title":"Cellular and molecular mechanisms of cyclosporin nephrotoxicity","volume":"1","author":"Kopp","year":"1990","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jaip.2022.08.025_bib20","first-page":"384","article-title":"Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies","volume":"7","author":"Olyaei","year":"2001","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.jaip.2022.08.025_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/164_2021_553","article-title":"Mechanistic target of rapamycin (mTOR) inhibitors","volume":"272","author":"Wang","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jaip.2022.08.025_bib22","first-page":"785","article-title":"Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis","volume":"79","author":"Lee","year":"2020","journal-title":"Z\u00a0Rheumatol"},{"key":"10.1016\/j.jaip.2022.08.025_bib23","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2022.08.025_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/annrheumdis-2020-218992","article-title":"Age-based (<65 vs \u226565 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry","volume":"80","author":"Winthrop","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2022.08.025_bib25","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaip.2022.08.025_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1399-0012.2010.01255.x","article-title":"Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipients: an emerging clinical phenomenon?","volume":"25","author":"Boddana","year":"2011","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jaip.2022.08.025_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11894-016-0491-3","article-title":"Gastrointestinal disorders associated with common variable immune deficiency (CVID) and chronic granulomatous disease (CGD)","volume":"18","author":"Uzzan","year":"2016","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jaip.2022.08.025_bib28","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12879-019-4022-3","article-title":"A\u00a0nearly fatal primary Epstein-Barr virus infection associated with low NK-cell counts in a patient receiving azathioprine: a case report and review of literature","volume":"19","author":"Honkila","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jaip.2022.08.025_bib29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s10875-021-00980-1","article-title":"The ever-increasing array of novel inborn errors of immunity: an interim update by the IUIS committee","volume":"41","author":"Tangye","year":"2021","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib30","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.jaip.2021.05.004","article-title":"A\u00a0toolkit and framework for optimal laboratory evaluation of individuals with suspected primary immunodeficiency","volume":"9","author":"Knight","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.08.025_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2021.01.003","article-title":"Severity grading system for acute allergic reactions: a multidisciplinary Delphi study","volume":"148","author":"Dribin","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib32","series-title":"Subcutaneous and intramuscular immune globulin therapy","author":"Jolles","year":"2022"},{"key":"10.1016\/j.jaip.2022.08.025_bib33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/cei.12485","article-title":"Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease","volume":"179","author":"Jolles","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jaut.2013.06.006","article-title":"Treg and CTLA-4: two intertwining pathways to immune tolerance","volume":"45","author":"Walker","year":"2013","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaip.2022.08.025_bib35","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib36","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s12185-020-02834-9","article-title":"Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy","volume":"111","author":"Ureshino","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jaip.2022.08.025_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.08.025_bib38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.23822\/EurAnnACI.1764-1489.22","article-title":"New therapeutic approach by sirolimus for enteropathy treatment in patients with LRBA deficiency","volume":"49","author":"Azizi","year":"2017","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib39","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \u201cactivated PI3K\u03b4 syndrome\u201d\u2014targeted therapy with the PI3K\u03b4 inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.08.025_bib40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaip.2022.08.025_bib41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.08.025_bib42","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.08.025_bib43","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s12325-017-0636-2","article-title":"A\u00a0review of chronic granulomatous disease","volume":"34","author":"Arnold","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2022.08.025_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s002280050720","article-title":"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone","volume":"56","author":"Varis","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2022.08.025_bib45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2125.2001.01372.x","article-title":"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects","volume":"51","author":"Lebrun-Vignes","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2022.08.025_bib46","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2165\/00002018-199309040-00003","article-title":"Adverse effects of intravenous immunoglobulin","volume":"9","author":"Misbah","year":"1993","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2022.08.025_bib47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.29262\/ram.v61i3.37","article-title":"Adverse effects with ambulatory intravenous immunoglobulin administration in adult patients with common variable immunodeficiency [in Spanish]","volume":"61","author":"Rodr\u00edguez-Mireles","year":"2014","journal-title":"Rev Alerg Mex"},{"key":"10.1016\/j.jaip.2022.08.025_bib48","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jcph.1889","article-title":"Anaphylaxis to subcutaneous immunoglobulin in a severe combined immunodeficiency patient","volume":"61","author":"Castano-Jaramillo","year":"2021","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"Suppl","key":"10.1016\/j.jaip.2022.08.025_bib49","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib50","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0140-6736(91)90147-H","article-title":"Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion","volume":"338","author":"Gardulf","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.08.025_bib51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00063030-200721020-00005","article-title":"Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route","volume":"21","author":"Gardulf","year":"2007","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaip.2022.08.025_bib52","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaci.2011.06.047","article-title":"The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature","volume":"129","author":"Rachid","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaip.2017.05.024","article-title":"Respiratory infections and antibiotic usage in common variable immunodeficiency","volume":"6","author":"Sperlich","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.08.025_bib54","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jaip.2020.08.016","article-title":"Increased respiratory viral detection and symptom burden among patients with primary antibody deficiency: results from the BIPAD study","volume":"9","author":"Ponsford","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.08.025_bib55","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s10875-022-01206-8","article-title":"Predictive factors for and complications of bronchiectasis in common variable immunodeficiency disorders","volume":"42","author":"Sperlich","year":"2022","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib56","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaci.2013.11.043","article-title":"Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts","volume":"133","author":"Shearer","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib57","doi-asserted-by":"crossref","unstructured":"Shields AM, Faustini SE, Hill HJ, Al-Taei S, Tanner C, Ashford F, et\u00a0al. SARS-CoV-2 vaccine responses in individuals with antibody deficiency: findings from the COV-AD study. J Clin Immunol 42:923-934.","DOI":"10.1007\/s10875-022-01231-7"},{"key":"10.1016\/j.jaip.2022.08.025_bib58","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s10875-022-01223-7","article-title":"COVID-19 vaccine uptake and efficacy in a national immunodeficiency cohort","volume":"42","author":"Ponsford","year":"2022","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s10875-021-01158-5","article-title":"Persistent COVID-19 infection in Wiskott-Aldrich syndrome cleared following therapeutic vaccination: a case report","volume":"42","author":"Bradley","year":"2022","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1556\/EUJMI-D-14-00026","article-title":"Pseudomonas infection in antibody deficient patients","volume":"4","author":"Duraisingham","year":"2014","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"10.1016\/j.jaip.2022.08.025_bib61","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.2019000924","article-title":"Virus-specific T-cell therapies for patients with primary immune deficiency","volume":"135","author":"Keller","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.08.025_bib62","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2022.08.025_bib63","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaip.2022.08.025_bib64","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2022.08.025_bib65","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.2020008187","article-title":"How I use allogeneic HSCT for adults with inborn errors of immunity","volume":"138","author":"Burns","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2022.08.025_bib66","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s10875-021-00971-2","article-title":"Hematopoietic stem cell transplantation resolves the immune deficit associated with STAT3-dominant-negative hyper-IgE syndrome","volume":"41","author":"Harrison","year":"2021","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2022.08.025_bib67","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fped.2020.00575","article-title":"Hematopoietic stem cell transplantation and vasculopathy associated with STAT3-dominant-negative hyper-IgE syndrome","volume":"8","author":"Ponsford","year":"2020","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaip.2022.08.025_bib68","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12016-021-08916-8","article-title":"future of therapy for inborn errors of immunity","volume":"63","author":"Perez","year":"2022","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822008601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822008601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:34:40Z","timestamp":1761975280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822008601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2213219822008601"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.08.025","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppression in Patients With Primary Immunodeficiency\u2014Walking the Line","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}